Meta-analysis of clinical efficacy and safety of kidney Tonifying therapy in the treatment of interstitial lung disease

Objective:To evaluate the efficacy and safety of kidney tonifying therapy in the treatment of Interstitial Lung Disease(ILD).Methods:We searched Wanfang Data,CNKI,CBM,VIP,Pub Med,EMBASE,Web of science and Cochrane Library for Randomized Controlled Trials(RCTs)of kidney tonifying therapy in the treatment of ILD.The retrieval time was from the establishment of the database to December 15,2020.Rev man 5.3 software was used to analyze and summarize the collected literature,and the methodological quality of the included studies was evaluated by the bias risk assessment scale of Cochrane Collaboration Network.Results:A total of 15 articles with 1045 patients were included.The results of meta-analysis showed that compared with the control group treated with conventional western medicine alone,kidney tonifying therapy or combined with conventional western medicine was beneficial to improve the clinical total effective rate[RR=1.33(95%CI 1.24-1.43),P<0.00001].At the same time,compared with the control group treated with routine western medicine,kidney tonifying therapy or combined with routine western medicine can improve cough and wheezing symptoms of patients[MD=-0.62(95%CI-0.78~-0.46),P<0.00001]and MD=-0.79(95%CI-0.18~-0.49),P<0.00001].However,there was no significant improvement in 6-minute walk test and lung function(DLCO%)(P>0.05);only one study reported 7 patients with adverse reactions,but after corresponding treatment,the symptoms were significantly relieved.The analysis of the characteristics of intervention measures in the treatment group showed that there were a total of 80 traditional Chinese medicines involved,of which Shu Dihuang appeared the most frequently,and the tonic drugs were used the most.The two meridians of the lung and kidney appear most frequently.Among the four qi and five flavors,warm and sweet medicines have the highest frequency.Conclusion:Adopting kidney-tonifying method or combined with conventional Western medicine treatment can improve the total clinical effectiveness of patients.Adopting kidney-tonifying method or combined with conventional Western medicine treatment to improve symptoms such as coughing and wheezing.No serious adverse reactions have been reported,and the safety is reliable.Due to the low quality of the included literature,the results of this study need to be verified by high-quality,large sample randomized controlled trials.

Regulating and tonifying spleen and kidney traditional Chinese medicine in the treatment of chronic uric acid nephropathy: A systematic review

Objective:To systematically evaluate the efficacy and safety of traditional Chinese medicine for regulating spleen and kidney.Methods:We developed a search strategy and then retrieved the database including CNKI,Wanfang data knowledge service platform,VIP journals resource integration service platform,PubMed,Embasefor randomized controlled trial of regulating spleen and kidney traditional Chinese medicine compared with conventional western medicine in the treatment of chronic uric acid nephropathy.The search deadline was set to June 30,2020.For the included literature,we applied the cochrane collaboration network risk bias assessment tool to evaluate the methodological quality,and evaluated the level of evidence according to GRADE standards.Quantitative data was analyzed by RevMan5.3 software,and trial sequential analysis method was used to analyze its efficiency.Results:A total of 709 cases in 10 articles were included.Compared with the control group,the related traditional Chinese medicine group improved the effective rate[RR=1.45,95%CI(1.32,1.58)],reduced the level of UA[MD=-36.24,95%CI(-41.03,-31.45)],BUN[SMD=-1.27,95%CI(-1.47,-1.07)]and SCR[MD=-36.33,95%CI(-55.79,-16.87),P=0.0003],the difference between the two groups was statistically significant(P<0.05).There was no evidence that a significant adverse reaction occurred.The results of TSA analysis showed that the Chinese medicine group had definite evidence for improving the efficiency.According to the GRADE evaluation criteria,the efficiency,UA,BUN and SCR outcome indicators were extremely low-quality evidence.Conclusions:Traditional Chinese medicine for regulating spleen and kidney in the treatment of chronic uric acid nephropathy improved efficiency,reduced the level of UA,BUN,SCR.Meanwhile,the therapy was proved to be safe.Nevertheless,the conclusions need further high-quality evidence to support.

Theoretical Discussion on Treatment of Cubital Tunnel Syndrome Based on Theory of Liver,Spleen and Kidney

Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second highest among peripheral nerve entrapment diseases,and it is one of the common clinical diseases.The theory of liver,spleen and kidney can guide the treatment of cubital tunnel syndrome with traditional Chinese medicine and acupuncture.By discussing the traditional Chinese medicine(TCM)pathogenesis and treatment principles of cubital tunnel syndrome,it provides modern medical theoretical support for TCM treatment of cubital tunnel syndrome.

Professor Fengjie He’s Experience in Treating Polycystic Ovary Syndrome of Kidney Asthenia and Liver Depression

Polycystic ovary syndrome is a common reproductive endocrine metabolic disease in clinic.Professor Fengjie He has accumulated rich clinical experience in the process of diagnosis and treatment of the disease.He believes that the key to the pathogenesis of the disease is the dysfunction of the reproductive axis of“kidney-Tiangui-Chongren-uterus,”which is based on kidney deficiency and involves the liver and spleen.Clinically,patients with kidney deficiency and liver depression are common.The treatment takes tonifying the kidney and regulating the menstrual cycle as the main method,and the clinical effect is very effective.

Effectiveness of tonifying-kidney and regulating-liver therapy on diminished ovarian reserve: a systematic review and Meta-analysis of randomized controlled trials

OBJECTIVE: To evaluate the effectiveness of the Traditional Chinese Medicine tonifying-kidney and regulating-liver therapy on diminished ovarian reserve(DOR).METHODS: The literature was comprehensively searched up to August 2019 using four Chinese and three English electronic databases to extract randomized clinical trials(RCTs) comparing Traditional Chinese Medicine tonifying-kidney and regulating-liver prescriptions(combined with hormone therapy or not) with Western Medicine. Data quality evaluation was conducted using the Cochrane risk of bias tool. Meta-analysis was conducted using Revman 5.3 software with effect estimates presented as mean difference(MD), risk ratio(RR), and95% confidence interval(CI).RESULTS: A total of nine RCTs with 512 participants were extracted and eligible for Meta-analysis.There were no significant differences between Chinese medicine and Western Medicine on basal serum follicle-stimulating hormone(FSH) level(MD0.11, 95% CI-0.52 to 0.74, 392 participants, seven trials), anti-Müllerian hormone level(MD 0.48, 95%CI-0.62 to 1.58, 95 participants, two trials), and the FSH and luteinizing hormone ratio(MD 0.01,95% CI-0.95 to 0.96, 115 participants, two trials).Chinese medicine was more effective at improving Traditional Chinese Medicine symptom scores(TCMSS)(MD-2.39, 95% CI-3.83 to-0.94, 160 participants, three trials), effective rate of TCMSS(RR1.18, 95% CI 1.02 to 1.36, 160 participants, three trials), antral follicle count(AFC)(MD 0.55, 95% CI 0.05 to 1.04, 155 participants, three trials), and FSH levels at 3 months post-treatment(MD-4.77, 95% CI-6.09 to-3.45, 137 participants, two trials).CONCLUSION: Compared with Western Medicine,tonifying-kidney and regulating-liver therapy is more effective at relieving symptoms and improving AFC and FSH at 3 months post-treatment.

Influence of electroacupuncture therapy of tonifying the kidney and regulating governor vessel on Aβ related degradation enzymes in the hippocampus of a rat model of Alzheimer's disease induced by Aβ_(1-42)

Objective： To explore influence of electroacupuncture（EA） therapy of tonifying the kidney and regulating governor vessel on amyloid beta（Aβ） related degradation enzymes in the hippocampus of a rat model of Alzheimer＇s disease（AD） induced by Aβ（1-42）.Methods： Forty Wistar male rats were randomly divided into 4 groups： a normal group, a sham operation group, a model group and an EA group, 10 rats in each one. The rats in normal group were normally fed. The rats in sham operation group were bilaterally injected in the hippocampus with 5 μL of saline and they were normally fed after the injection. The rats in the model group and the EA group were bilaterally injected in the hippocampus with 5 μL of Aβ（1-42） on each side. Rats in the EA group received EA of 5 Hz continuous wave at the ＂Bǎihuì（百会 GV20）＂ and bilateral ＂Shènshū（肾俞 BL23）＂ for a duration of 15 min per time every day and continuously for 15 days. After 15 days, the hippocampal expression levels of insulin degrading enzyme（IDE）, lipoprotein（LPL）, transthyretin（TTR）, apolipoprotein E（APoE）,a2 macroglobulin（a2 M） and Aβ（1-42） of the 4 groups were tested by Western blot.Results： Compared with the sham operation group, the expression levels of IDE, LPL, TTR, APoE and a2 M in the hippocampus were significantly lower（P〈 0.05, P〈 0.01） and the expression of Aβ（1-42） was significantly higher（P〈 0.01） in the model group. Compared with the model group, the expression levels of IDE, LPL, TTR,APoE and a2 M in the hippocampus of these rats were significantly lower（P〈 0.05,P〈 0.01）, the expression of Aβ（1-42） was significantly higher（P〈 0.01） in the EA group.Conclusion： EA therapy of tonifying the kidney and regulating governor vessel can enhance the expression of IDE, LPL, TTR, APoE, and a2 M in the hippocampus of AD rats injected by Aβ（1-42）, and may consequently promote the degradation of aβ（1-42） to help improve the pathological manifestations of AD and therefore delay its progression.

Tonifying Kidney, Lung, and Spleen Combined with Western Medicine for Stable Chronic Obstructive Pulmonary Disease: A Systematic Review

Introduction:This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney,lung,and spleen(TKLS)combined with Western medicine for stable chronic obstructive pulmonary disease(COPD).Materials and Methods:Randomized controlled trials(RCTs)of TKLS for stable COPD were searched from four databases including Pub Med,the Cochrane Library,China Biology Medicine,and China National Knowledge Infrastructure from inception to December 2017.Two reviewers independently screened the literature,extracted the data,and assessed the risk of bias in the included studies.Rev Man5.3 software was used for meta-analysis.Results:Fourteen RCTs involving 1339 patients with stable COPD were included.Five of the included articles described the specific method of randomization,1 of them was double-blind method research,and 1 of them was single-blind method research.Compared with the conventional Western medicine(CWM)group,the use of TKLS,if combined with CWM demonstrated significantly improved effective rate(relative risk=1.25,95%confidence interval[CI]:1.18–1.33,P<0.00001),decreased traditional Chinese medicine syndrome score(mean difference[MD]-5.72,95%CI:-8.31 to-3.14,P<0.0001),Decreased St George's Respiratory Questionnaire total score(MD-7.39,95%CI:-10.46 to-4.31,P<0.00001),increased 6-min walk distance in meters(MD 78.46,95%CI:60.18–96.73,P<0.00001),increased forced expiratory volume 1%(MD 6.49,95%CI:3.64–9.33,P<0.00001),increased CD4(MD 9.84,95%CI:6.73–12.94,P<0.00001),CD8(MD-1.84,95%CI:-3.62 to-0.06,P=0.04)and CD4/CD8(MD 0.26,95%CI:0.20–0.32,P<0.0001),and increased immunoglobulin M(MD 0.15,95%CI:0.10–0.20 P<0.00001)..Conclusions:For stable COPD,TKLS combined with CWM is superior to CWM alone with regard to clinical effectiveness,symptoms,and quality of life.The above conclusion needs to be validated by further well-designed,multicentric,large-scale,double-blinded RCTs.

基于TLR4/NF-κB通路调补肺肾法干预细胞自噬对COPD肺血管重塑的影响和机制

目的基于Toll样受体4(TLR4)/核转录因子-κB(NF-κB)通路研究调补肺肾法干预细胞自噬对慢性阻塞性肺疾病(COPD)肺血管重塑的影响和机制。方法取SD大鼠采用香烟烟雾暴露结合反复细菌感染的方案建立COPD模型,随机分为3组,模型组、补肺益肾方(3.7 g/kg)组、补肺益肾方(3.7 g/kg)+脂多糖(LPS)(TLR4激活剂,15 mg/kg)组,每组12只,另取12只大鼠正常呼吸并气管滴注等剂量生理盐水作为对照组,经补肺益肾方、LPS对大鼠分组干预后,检测各组大鼠肺功能指标:潮气量(TV)、呼气峰流速(PEF)、第0.3秒用力呼气容积(FEV0.3)/用力肺活量(FVC)。以HE染色检测各组大鼠肺组织病理形态和肺血管重塑,比较其管壁厚度(WT)占血管直径(VD)百分比WT/VD(%)、管腔面积(LA)占血管总面积(TA)百分比LA/TA(%)。以免疫荧光染色检测各组大鼠肺组织内肺血管内皮标记物CD34表达。以酶标仪检测各组大鼠肺泡灌洗液(BALF)及血清促炎因子:肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-17水平。以免疫印迹法检测各组大鼠肺组织自噬及TLR4/NF-κB信号通路相关蛋白表达。结果与对照组相比,模型组大鼠肺组织呈现明显病理损伤及肺血管重塑症状,TV、PEF、FEV0.3/FVC、LA/TA、肺组织Beclin-1蛋白表达与LC3Ⅱ/LC3Ⅰ显著降低(P<0.05),WT/VD、CD34相对阳性表达、BALF及血清促炎因子TNF-α与IL-17水平、肺组织TLR4蛋白表达与p-NF-κB p65/NF-κB p65显著升高(P<0.05)。与模型组相比,补肺益肾方组大鼠肺组织损伤及肺血管重塑症状减轻,TV、PEF、FEV0.3/FVC、LA/TA、肺组织Beclin-1蛋白表达与LC3Ⅱ/LC3Ⅰ升高(P<0.05),WT/VD、CD34相对阳性表达、BALF及血清促炎因子TNF-α与IL-17水平、肺组织TLR4蛋白表达与p-NF-κB p65/NF-κB p65降低(P<0.05)。与补肺益肾方组相比,补肺益肾方+LPS组大鼠肺组织损伤及肺血管重塑症状加重,TV、PEF、FEV0.3/FVC、LA/TA、肺组织Beclin-1蛋白表达与LC3Ⅱ/LC3Ⅰ降低(P<0.05),WT/VD、CD34相对阳性表达、BALF及血清促炎因子TNF-α与IL-17水平、肺组织TLR4蛋白表达与p-NF-κB p65/NF-κB p65升高(P<0.05)。结论补肺益肾方可通过抑制TLR4/NF-κB信号而抑制COPD体内炎症,并增强自噬,进而减轻大鼠肺组织病理损伤和肺血管重塑,改善其肺功能。

基于《证治汇补·哮病》探析儿童哮喘防治思路

儿童哮喘是儿科常见疾病之一,明末清初医家李用粹所著《证治汇补·哮病》总结前人医家的观点,指出“非时之感”为本病的外在诱因,“胶固之痰”为内在根本,“壅塞之气”则是病机所在。儿童哮喘急性发作期以肺气壅塞为主,治疗应当以宣肺理气为主,兼顾疏风散邪和化痰祛饮;缓解期的治疗则当以祛除“伏痰”为主要目标,化痰祛饮和补虚扶正双管齐下,其中补虚尤当注重补脾胃,且补脾胃当重健运而非进补之法;而对“非时之感”的防范和治疗则应当贯彻疾病的全过程,尤其在缓解期和迁延期,需意识到其仍有未尽之风痰,邪不去则正难复,此外也要将患儿精神心理因素纳入防治的范畴;愈后当防复发,日常饮食生活调摄当尤为重视,家长应积极引导患儿养成健康的生活习惯。

基于补肾理肺思想运用大温中饮治疗多囊卵巢综合征的临证体会

多囊卵巢综合征(PCOS)是临床多发疾病,临床常表现为月经异常、痤疮、多毛、肥胖等,在中医学看来这与肾精不足、肺失宣降的病机密切相关。肾精不足则精不化血,冲任血海空虚,引起月经后期、闭经。肺失宣降,皮毛失于滋养,气血不能输布,毛窍腠理不通发为痤疮、多毛。肺气不利则通调水道功能失司,津液代谢障碍产生痰、湿、水、饮等病理产物,形成肥胖体型。笔者基于中医学理论体系,结合自身长期的临床实践,认为可以通过补肾理肺法来治疗多囊卵巢综合征。《景岳全书·新方八阵·散阵》中大温中饮具有补肾宣肺、行气活血、温化痰饮功效,切合PCOS病机,在临床实践中取得满意疗效,实现了古方为今所用,为PCOS的治疗提供了宝贵的治疗办法,值得临床推广应用。

陈宪海辨证分型辨治慢性阻塞性肺疾病稳定期

陈宪海教授认为慢性阻塞性肺疾病(COPD)稳定期病位在肺,属本虚标实,本虚以肺脾肾气虚为主,标实以痰瘀交阻多见,特点为"虚实并见、互为因果",宜补虚泻实,分清主次,辨证分型,肺脾两虚-健脾益肺(玉屏风散合六君子汤)、肺肾两虚-调补肺肾(肺肾气虚,西洋参、冬虫夏草、枸杞子、女贞子、淫羊藿、山茱萸、五味子等,补肺纳肾;肺肾阴虚-麦味地黄汤)、痰瘀搏结-化痰祛瘀(益气化痰祛瘀、养阴化痰祛瘀),强调综合治疗COPD,康复治疗,防治结合、中西医结合,缓解期服用百令胶囊,补益肺肾,以巩固疗效。

国医大师晁恩祥运用养阴益气法治疗肺痿经验

间质性肺疾病的病因复杂,目前病机尚未完全阐明。晁恩祥教授认为本病属于中医“肺痿”范畴,临证时应重视肺肾气阴亏虚、痰瘀阻肺之病机,提出“养阴益气、调补肺肾、化痰祛瘀”治疗原则。晁恩祥教授立足于中医基础理论,结合自身的临床经验,对患者进行辨证施治,取得了良好疗效。

基于双层频权剪叉算法探讨中药治疗重症肌无力用药规律

通过检索中国知网(CNKI)、万方数据库、维普数据库、中国生物医学文献数据库(CBM)等数据库中中医药治疗重症肌无力的文献,采用双层频权剪叉算法计算方剂的功效权值,并归一化各功效的权值,生成重症肌无力类方热图、网络图,对中药治疗重症肌无力的用药规律进行挖掘。结果共纳入文献68篇,整理得到124首中药复方,含单味药159味。热图及网络图分析结果得到治疗重症肌无力的中药可归为补心肝肺脾肾、平肝熄风、温阳祛湿、活血化瘀等16组功效组合,以及治疗MG的代表药对组合有26组。分析结果显示重症肌无力的方剂治疗注重调理五脏,且各有偏重。针对脾胃,注重补益脾胃、健脾和胃;针对肝胆,注重清肝、疏肝、平肝、清胆;针对肺,则先辨寒热,寒者多用细辛、麻黄宣发肺气、温肺化饮,热者多以黄芩、丹参、石膏、生地黄等清热泄热;针对心,除了注重清心补心,还注重活血化瘀;针对肾,则以温肾补肾为主,并兼顾肝脾,佐以祛风湿、除痹、强筋骨等药。研究结果为深入探索中药治疗重症肌无力的方法提供了借鉴。

基于五脏一体观从肺论治肾性水肿

水肿是肾脏病的常见症状,肾性水肿的本质即体内水液代谢失常,发病的基本病机为肺失通调、脾失转输、肾失开阖、三焦气化不利,故不能以单因素解释肾性水肿之全貌,且其病情反复、迁延难愈,单从肾治之疗效不显。基于“五脏一体观”,从肺与肾的关系、肺与肾性水肿发病的关系及现代研究等角度展开论述,强调辨证论治,临证首分虚实,实者予宣肺利水法、清肺解毒法、开郁行水法,虚者予补肺益肾法、温肺化水法,本虚和标实兼而有者,标本同治。

李时珍防治老年病学术思想探讨

探讨了李时珍在防治老年病、养生防病方面的学术思想 :注意护肺气 ,温胸阳 ,勿用寒凉 ;益胃气 ,升脾阳 ,治宜培补后天 ;顾护命门阳气 ,用药因人而异 ;消郁滞 ,通痰阻 ,调畅气机。

补肾调周法治疗月经性哮喘探析

月经性哮喘的发病与月经周期相关,基于调周法的理论指导,探讨月经性哮喘的独特病机与辨治要点。该病发时处于经前后半期或行经期,常见热象,证候类型主要有肝火犯肺、痰热壅肺;平时以肾阴亏虚、肺脾气弱为主。结合经后期、经前期的阴阳消长特点,经后期强调养血滋阴补肾、益气健脾化痰,经前期治从养血益气助阳、清热降逆化痰。

从奇经论治结缔组织相关间质性肺疾病

[目的]探讨应用奇经理论治疗结缔组织相关间质性肺疾病的合理性和可行性。[方法]通过临床学习,结合奇经理论,解析结缔组织相关间质性肺疾病相关奇经医理,从病象特征、病因病机、治疗方法等方面分析运用奇经理论治疗结缔组织相关间质性肺疾病的学术观点和临床经验,并列举古今验案佐证。[结果]查结缔组织相关间质性肺疾病病位,可为奇经诸脉所部,循疾病传变,累及奇经是其最终转归;析临床症状,可谓奇经诸脉交病之象。寒遏督阳、奇经虚损、奇络瘀滞是其重要病因病机。临证施治时可从督脑内外之寒论治,予温督祛寒;从奇经虚损论治,予补益奇经、通阳摄阴;从奇经血络论治,予通调阴阳之络诸法。所举验案分别为悲伤耗气及年老正虚,外邪侵袭,郁遏督阳,凝滞气血,更伤气阳,虚、邪、瘀胶结不去,深入骨节、脏腑发为痹证,治疗分别以清燥汤祛奇邪、补奇虚,以玉屏风散合二陈汤加减补肺化浊、通和奇脉,临床疗效显著。[结论]从奇经论治结缔组织相关间质性肺疾病是从脏腑论治的有效补充和完善。

基于五脏相关论治难治性胃食管反流病

难治性胃食管反流病成因繁多,临床上仅以常规方法从胃和食管论治本病,难收佳效。五脏相关是中医学整体观念的重要内容。基于五脏相关理论,从脾、肺、肝、肾、心辨治出发,分析各脏与难治性胃食管反流病病机的关系,基于建中理脾、宣降肺气、抑木扶土、温阳益肾、益火养心的原则,指导难治性胃食管反流病的临床治疗,常可速达病所,祛除顽疾,可为临床诊疗提供借鉴。并附验案1则加以阐明。

调补肺肾法对慢阻肺稳定期综合预后指标影响的临床研究

目的:探讨调补肺肾法治疗慢性阻塞性肺疾病(COPD)稳定期的临床疗效,评价治疗COPD稳定期患者的预后作用。方法:选取2014年1月至2015年6月在我院就诊的COPD稳定期患者84例,采用随机方法将患者分为治疗组(42例)和对照组(42例),治疗组给予常规治疗和口服调补肺肾方药,而对照组仅给予常规治疗,观察2组临床疗效及综合预后情况。结果:2组治疗后中医症候总积分较治疗前均有所下降,而治疗组较对照组下降幅度明显(P<0.05);治疗组治疗总有效率为92.86%,明显高于对照组的64.29%,治疗组疗效优于对照组(P<0.05);2组治疗后肺功能均有所改善,其中治疗组FEV1和FEV1/预计值(%)、FVC和FVC/预计值(%)等指标改善情况优于对照组(P<0.05);治疗组治疗后呼吸困难情况、6 min行走距离和BODE评价总分均较治疗前有改善(P<0.05),而对照组治疗后6 min行走距离和BODE评价总分亦较治疗前有所改善(P<0.05),但呼吸困难情况改善不明显(P>0.05),治疗组治疗后呼吸困难情况、6 min行走距离和BODE评价总分均较对照组治疗后明显改善(P<0.05)。治疗组治疗后各免疫指标、生活质量指标和急性发作次数较对照组均有所改善(P<0.05)。结论:调补肺肾法能有效治疗COPD稳定期患者,改善患者预后情况。

《素问·灵兰秘典论》肺主治节理论及运用探讨

《素问·灵兰秘典论》借以官职的隐喻方式阐明各脏腑的贵贱关系,强调了肺对心而言具有重要的辅佐作用。通过对"肺者,相傅之官,治节出焉"的诠释,揭示了"肺主治节"的含义,即肺能够调理和使心脏规律的活动。心藏神理论奠定了心为君主之官,而肺主气与心主血的关系,体现在"肺为相傅之官"能够助心行血,调节心脏活动的规律,并且与心神的调控有一定关系。因此,提出补肺助心法治疗心虚证,开鬼门、发汗法治疗心阳虚衰引起的水肿以及从肺论治情志病等诸多方面,具有非常重要的临床启示及指导意义。